Welcome to our dedicated page for Halberd news (Ticker: HALB), a resource for investors and traders seeking the latest updates and insights on Halberd stock.
Halberd Corporation (OTC: HALB) generates a steady stream of news centered on its healthcare technology initiatives, research collaborations, and funding developments. Investors and observers following HALB news can expect updates on traumatic brain injury (TBI) research, PTSD and mental health programs, AI-driven behavioral platforms, and partnerships with medical and technology organizations.
Recent press releases highlight Halberd’s work with Mississippi State University on a proprietary nasal spray intended to mitigate the effects of TBI, including plans for advanced Phase-2 animal studies. News items also cover the company’s acquisition and development of NeuroSense AI, a behavioral intelligence platform that combines ultrasonic vocalization analysis, micro-movement tracking, and social behavior monitoring with Claude AI-powered interpretation for preclinical TBI and neurological research.
Another major theme in HALB news is its LDX and WatchDawg programs for PTSD, suicidal ideation, and related mental health challenges, particularly among veterans. Halberd and its partners report pilot study results using LDX-based therapies, nutraceuticals, yoga and meditation, and continuous wearable monitoring via Athena GTX’s technology. Announcements describe plans for larger clinical studies, solicitations for nephrologists and clinicians, and cooperative efforts with Athena Telemedicine Partners, LLC.
News releases also discuss funding and contract developments, including a substantial contract commitment involving Defense Atomics Corporation to support combined CRISPR/nanotechnology stem cell treatment with Halberd’s LDX protocol and WatchDawg monitoring. Readers of HALB news can use this page to follow progress on government contract proposals, private investment efforts, regulatory planning, and technical milestones in AI-powered healthcare platforms.
For anyone tracking HALB stock or its healthcare projects, the news feed provides context on how Halberd’s research programs, partnerships, and technology demonstrations evolve over time.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Halberd Corporation (OTC PINK: HALB) reported a productive first quarter of 2023, achieving significant milestones in its research and development efforts. Notably, Halberd successfully eradicated antibiotic-resistant bacteria and fungi using its patented laser technology, as confirmed by the CDC. The company has received additional samples from the CDC for further testing. Additionally, Halberd filed Form 15 with the SEC, removing the YIELD designation from its stock symbol. The company secured a contract with Mississippi State University for preclinical testing of a nasal spray to treat Traumatic Brain Injury (TBI), with 75% of the costs prepaid. Halberd continues to pursue government contracts and partnerships with pharmaceutical companies for FDA approval funding, while maintaining a strategic focus on non-dilutive funding opportunities.
Halberd Corporation (OTC PINK:HALB) recently featured President & CEO William A. Hartman, Chief Technical Officer Dr. Mitchell S. Felder, and YSU Professor Dr. Wm. Gregg Sturrus in an interview on 'The Street Reports.' They discussed significant strides in research aimed at eradicating antibiotic-resistant bacteria and harmful fungi supplied by the CDC.
The laser eradication technique, led by Dr. Sturrus, has successfully neutralized various pathogenic strains. Dr. Felder emphasized that no tested pathogens have developed resistance to this extracorporeal method. Additionally, Halberd has initiated pre-clinical testing for a nasal spray designed to mitigate head trauma effects. Hartman expressed optimism about advancing this research into viable therapeutic solutions for chronic diseases and injuries.
Halberd Corporation (OTC PINK:HALB) is collaborating with Youngstown State University (YSU) on innovative research targeting antibiotic-resistant bacteria and Candida auris. This research was highlighted in a recent CBS news segment. Under the guidance of Dr. Cooper, researchers are utilizing laser exposure to effectively kill 90-95% of harmful bacteria in under 10 minutes while preserving beneficial strains. The CDC has shown interest by providing additional strains for testing Halberd's patented laser eradication technique. This new extracorporeal method aims to treat diseases by cleansing infected bodily fluids outside the body, minimizing reliance on antibiotics. Halberd's developments reflect its commitment to advancing disease treatment methodologies and enhancing shareholder value.
Halberd Corporation (OTC PINK:HALB) has initiated preclinical testing of a novel nasal spray aimed at mitigating the adverse effects of Traumatic Brain Injury (TBI) at Mississippi State University (MSU). This study marks a significant milestone as it aims to measure the relationship between head impact severity and brain injury, a first in this field. The nasal spray is designed to inhibit the production of inflammatory cytokines and neurotransmitters following head trauma, potentially improving outcomes when administered shortly after injury. Funded entirely by Epidemiologic Solutions Corporation, the project has 75% of its costs covered and is structured to comply with FDA regulations, paving the way for market approval. The product targets a substantial market gap, with no other treatments addressing TBI prevention in this manner.
Halberd Corporation (OTC PINK:HALB) reported a successful meeting with the CDC on March 29, 2023, highlighting its achievement in eradicating antibiotic-resistant strains of E. coli and Candida auris. The meeting detailed successful testing conducted at Youngstown State University by Drs. Chester Cooper and W. Gregg Sturrus. The CDC representatives expressed interest in future collaborations and committed to providing more dangerous bacterial and fungal strains for testing. Halberd plans follow-up meetings to expedite development and explore funding opportunities for its patented technologies.
Halberd Corporation has entered an agreement with Mississippi State University to conduct pre-clinical testing of its patent-pending nasal spray aimed at mitigating the effects of Traumatic Brain Injury (TBI). The testing will start on April 10, 2023, and concludes by October 10, 2023. Dr. Russell Carr will oversee the research. Halberd's spray is intended to block the over-production of inflammatory proteins following head trauma, potentially benefiting military personnel and athletes. This initiative underscores Halberd's commitment to addressing neurological complications associated with TBI.